Androgenetic alopecia: minoxidil, finasteride, dutasteride, and the 2026 pipeline

Androgenetic alopecia — male and female pattern hair loss — affects roughly half of men by their fifties and a large share of women over their lifetime. Despite how common it is, the toolbox of FDA-approved medications has barely changed in three decades. As of mid-2026, only two drugs are FDA-approved to treat pattern hair loss: topical minoxidil (approved 1988, originally Rogaine) and oral finasteride 1 mg (approved 1997, originally Propecia). Both predate the smartphone.

That stagnation is the context patients need before they read anything else. Most of what has changed in hair-loss treatment since the 1990s is the rise of off-label oral therapies — low-dose oral minoxidil and oral dutasteride — and a wave of new drugs now moving through late-stage clinical trials. This article separates what is approved, what is used off-label, and what is actually coming.

What drives pattern hair loss

In genetically susceptible follicles, the hormone dihydrotestosterone (DHT) — a derivative of testosterone — shortens the growth (anagen) phase of the hair cycle and progressively miniaturizes the follicle. The result is finer, shorter, lighter hair and eventually no visible hair. Male pattern loss typically follows the receding hairline and crown-thinning sequence; female pattern loss tends to be diffuse central thinning with a preserved frontal hairline.

Treatments work by two broad strategies: reducing the androgen signal (5-alpha-reductase inhibitors that lower DHT, or androgen-receptor blockers) or extending the hair growth phase (minoxidil). Neither strategy regrows a fully bald scalp — once a follicle has stopped producing visible hair, medication cannot reliably revive it. The realistic goal of medical therapy is to slow further loss and thicken remaining hair, which is why earlier intervention does better.

The FDA-approved foundation

Topical minoxidil (Rogaine and generics)

Topical minoxidil is the only FDA-approved first-line option for both men and women, available over the counter as a 2% solution or 5% solution/foam. Its mechanism is not fully understood but is thought to involve opening ATP-sensitive potassium channels in the dermal papilla, prolonging anagen and improving follicular blood flow. Visible benefit typically takes three to six months of daily use, and an initial shedding phase in the first few weeks is common and expected — it reflects follicles cycling into a new growth phase, not treatment failure.

Topical minoxidil's main limitation is adherence: it must be applied to a dry scalp twice daily (for the 2% solution) or once or twice daily (5%), the hair must be dry before styling, and discontinuation leads to loss of any regrown hair within months. Common side effects include scalp irritation, unwanted facial hair (hypertrichosis) if the solution runs, and rarely cardiovascular effects at higher systemic absorption.

Oral finasteride 1 mg (men)

Oral finasteride is FDA-approved for men only. It inhibits the type II 5-alpha-reductase enzyme, reducing scalp-tissue DHT by roughly 60% and serum DHT by about 70%. In clinical trials it slowed hair loss and increased hair counts in the crown and, to a lesser degree, the frontal scalp in a majority of men.

The side-effect profile is what makes finasteride a careful decision rather than a default. In registration trials, sexual side effects — reduced libido, erectile dysfunction, reduced ejaculate volume — occurred in roughly 1–2% of men and resolved in most after stopping. A subset of men report persistent symptoms after discontinuation ("post-finasteride syndrome"), an area of active study and debate. Finasteride can lower prostate-specific antigen (PSA), which is relevant for prostate-cancer screening. The FDA has required labeling to note the possibility of decreased libido, depression, and — more recently — warnings referencing suicidal ideation, and an October 2025 commentary argued the agency has not done enough to investigate the mental-health signal. Finasteride is strictly contraindicated in pregnancy and in women of childbearing potential, because it can cause genital abnormalities in a male fetus; pregnant women should not even handle crushed or broken tablets.

Off-label but commonly used

Most modern hair-loss prescribing now includes off-label oral agents, used when topical therapy is inadequate or adherence is poor. "Off-label" means the FDA has not approved the drug for this specific use; it does not mean experimental, and these prescriptions are common in dermatology practice.

Low-dose oral minoxidil

Low-dose oral minoxidil (LDOM) has become one of the most widely adopted off-label hair-loss therapies of the past five years. Typical ranges discussed in the literature are roughly 2.5–5 mg daily for men and 0.25–1.25 mg daily for women — far below the doses used for its original blood-pressure indication. A 2025 international Delphi consensus published in JAMA Dermatology offered guidance on initiating low-dose oral minoxidil, reflecting how mainstream it has become. Pooled data suggest efficacy broadly comparable to topical minoxidil with the practical advantages of better adherence, lower cost, and no scalp residue. Side effects are dose-dependent and include unwanted body hair growth (hypertrichosis, reported in roughly a quarter of patients in some series), transient shedding, and rarely lower blood pressure, ankle swelling, or ECG changes — which is why it belongs under medical supervision rather than self-prescribed.

Oral dutasteride

Dutasteride inhibits both type I and type II 5-alpha-reductase and lowers serum DHT by up to roughly 90% — more potently than finasteride. It is FDA-approved for benign prostatic hyperplasia (0.5 mg), not for hair loss, but is used off-label for male pattern loss, often as a second-line option when finasteride is insufficient. It has a much longer half-life (around five weeks), so effects and any side effects persist long after stopping. Dutasteride is approved for androgenetic alopecia in South Korea (2009) and Japan (2015); a 2025 Korean phase III trial found low-dose 0.2 mg dutasteride effective. The same pregnancy contraindication and sexual-side-effect considerations apply, more strongly.

Topical and compounded finasteride

There is no FDA-approved topical finasteride product. Compounded topical finasteride (often combined with minoxidil) is widely promoted as a way to reduce systemic exposure while still targeting scalp DHT, but compounding is not FDA-approved and quality varies. In April 2025 the FDA issued an alert warning that compounded topical finasteride carries risks — including local irritation and inadvertent transfer to others, particularly female partners — and reminded patients and prescribers that these products have not been evaluated for safety or effectiveness. Patients considering compounded topical finasteride should understand it is unapproved, ask about the source, and discuss transfer-prevention precautions.

Therapy for women

Women of childbearing potential generally cannot take finasteride or dutasteride. The mainstays for female pattern loss are topical or low-dose oral minoxidil and, where appropriate, anti-androgens such as spironolactone (off-label), sometimes combined with oral contraceptives. Diagnosis matters: diffuse shedding may be telogen effluvium, iron or thyroid deficiency, or post-COVID shedding rather than true androgenetic alopecia, and the workup differs.

Adjuncts beyond medication

Medical therapy is the backbone, but it is rarely the whole plan. Platelet-rich plasma (PRP) injections, low-level laser therapy (LLLT) caps, and — for stable, well-defined areas of loss — surgical hair transplantation are commonly layered on top of minoxidil and an anti-androgen, not instead of them. The evidence base for these adjuncts varies: transplant is the most effective option for permanently bald areas because it relocates DHT-resistant follicles, while PRP and LLLT have supportive but mixed data. This article focuses on the medications because they are the treatments almost every patient will use first and longest; the procedural options each warrant their own discussion.

The 2025–2026 pipeline: what is actually coming

After decades with no new mechanism of action, several candidates are now in late-stage trials. None is FDA-approved for hair loss yet, and projected timelines are estimates.

Clascoterone is the most advanced. Its 1% formulation is already FDA-approved as Winlevi for acne (2020). For hair loss, two identical Phase III trials (SCALP-1 and SCALP-2) enrolled 1,465 men across the US and Europe; the company announced topline results in December 2025 and plans FDA and EMA submissions after completing 12-month safety follow-up in spring 2026. If approved, clascoterone would be the first new mechanism of action for pattern hair loss since finasteride — a topical that blocks DHT at the receptor locally, potentially offering anti-androgen benefit without the systemic hormone suppression that drives finasteride's side-effect profile. The practical message for patients today: clascoterone for hair loss is not yet available, and any current "clascoterone for hair loss" use is off-label or investigational.

PP405 (Pelage, backed by ARCH Venture Partners and Google Ventures) takes a different approach entirely — reactivating dormant follicle stem cells rather than modulating androgens — and is entering Phase 3 trials in 2026, with approval not expected before 2027 at the earliest.

A practical framework

For most patients, a reasonable evidence-first sequence is:

1. Confirm the diagnosis. Androgenetic alopecia is patterned; diffuse shedding is something else. A dermatologist can distinguish these.
2. Start with an FDA-approved agent — topical minoxidil for both sexes, or oral finasteride for men who accept the side-effect profile.
3. Consider off-label oral options (low-dose oral minoxidil, dutasteride) when topical therapy is insufficient or adherence is the limiting factor, under medical supervision.
4. Set realistic expectations. Medical therapy slows loss and thickens existing hair; it does not resurrect a bald scalp. Combining therapies often outperforms any single agent.
5. Watch the pipeline — clascoterone may become a real option within the next year or two, especially for patients who cannot or will not take systemic anti-androgens.

What to ask your provider

• Is my hair loss actually androgenetic alopecia, or could it be telogen effluvium, a thyroid or iron issue, or another diagnosis? Treatment differs.
• Which FDA-approved option fits my sex, age, and family-planning situation? Finasteride and dutasteride are off-limits in pregnancy.
• If an off-label oral agent is recommended, what is the dosing rationale, the monitoring plan, and the side-effect watchlist?
• For compounded topical finasteride: is this an FDA-approved product, and what precautions prevent transfer to a partner?
• How long before I should expect to see whether this is working, and what is the plan if it isn't?

Pattern hair loss is chronic and progressive. The two approved drugs, used carefully and combined where appropriate, slow it for most people — and for the first time in a generation, genuinely new options are close enough to track.

Sources

• FDA approved products for alopecia — Drugs@FDA (minoxidil, finasteride labeling): https://www.accessdata.fda.gov/scripts/cder/daf/
• FDA alert on compounded topical finasteride products (April 2025): https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded
• Nohria A, et al. Low-dose oral minoxidil monotherapy vs. combination with dutasteride or finasteride for AGA. J Am Acad Dermatol. 2025;92(5):1159-1161: https://pubmed.ncbi.nlm.nih.gov/39894359
• Akiska YM, et al. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement. JAMA Dermatol. 2025;161(1):87-95: https://pubmed.ncbi.nlm.nih.gov/39565602
• Liu C, et al. Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review. Front Pharmacol. 2025;16:1556705: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1556705/full
• Efficacy and safety of low-dose (0.2 mg) dutasteride for male androgenic alopecia: a multicenter, randomized, double-blind, placebo-controlled Phase III trial. Ann Dermatol. 2025 (PMID 40736519): https://pmc.ncbi.nlm.nih.gov/articles/PMC12318778
• Clascoterone Phase 3 (SCALP) program and pipeline coverage, Cosmo Pharmaceuticals (December 2025): https://www.genengnews.com/topics/translational-medicine/stockwatch-cosmo-surges-40-on-baldness-candidates-phase-iii-data
• DelveInsight: Androgenetic Alopecia Pipeline Analysis 2025 (PP405, ET-02, ABS-201): https://www.delveinsight.com/report-store/androgenetic-alopecia-pipeline-insight